Joshua Grant, MD
Ophthalmology · Farmington Hills, MINPI 1447485461
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $10,642 of the $15,559 with a category attached, or 68.4%. Regeneron Healthcare Solutions, Inc. accounts for 77.6% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2023 at $6,579 and has fallen 91.3% since, to $569 in 2025. Among ophthalmology clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 155 payments — averaging $100.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$12K
- Alimera Sciences, Inc.$2K
- Apellis Pharmaceuticals, Inc.$575
- Genentech USA, Inc.$278
- Bausch & Lomb Americas Inc.$126
- Astellas Pharma US Inc$109
- plus $677 from 13 others
What the payments were for
- Speaking & faculty fees$10,64268%
- Travel & lodging$580%
- Food & beverage$4,86031%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 65 | $12,074 |
| Alimera Sciences, Inc. | 9 | $1,720 |
| Apellis Pharmaceuticals, Inc. | 21 | $575 |
| Genentech USA, Inc. | 12 | $278 |
| Bausch & Lomb Americas Inc. | 7 | $126 |
| Astellas Pharma US Inc | 5 | $109 |
| Sun Pharmaceutical Industries Inc. | 5 | $104 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 7 | $102 |
| Harrow Eye, LLC | 3 | $83 |
| AbbVie(2 entities) | 4 | $77 |
| Tarsus Pharmaceuticals, Inc. | 3 | $75 |
| Aerie Pharmaceuticals, Inc. | 4 | $50 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $46 |
| Alcon | 2 | $42 |
| Novartis | 2 | $28 |
| Boston Scientific | 1 | $20 |
| Coherus Oncology, Inc. | 1 | $19 |
| Merz Pharmaceuticals, LLC | 1 | $18 |
| Oyster Point Pharma, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,559 in reported general payments places this provider in the 95th percentile of 674 ophthalmology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 42 | $61,188 |
| Cyclosporine | 47 | $25,267 |
| XiidraLifitegrast | 13 | $23,614 |
| LumiganBimatoprost | 19 | $10,845 |
| Latanoprost | 292 | $6,499 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 26 | $5,259 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 132 | $3,728 |
| Timolol Maleate | 47 | $3,166 |
| Prednisolone Acetate | 56 | $3,056 |
| Bromfenac Sodium | 11 | $2,988 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 98 | $1,336 |
| Brimonidine Tartrate | 47 | $1,137 |
| Ketorolac Tromethamine | 23 | $1,065 |
| Dorzolamide Hcl | 24 | $524 |
| Ofloxacin | 11 | $214 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $77 | $72,03361 claims |
| Bausch & Lomb Americas Inc.Xiidra | $126 | $23,61413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 674 ophthalmology providers in Michigan.
Other ophthalmology in Farmington Hills
- Manjool ShahAnn Arbor$609K
- Gregory KatzYpsilanti$401K
- Timothy PageBirmingham$250K
- David ZacksAnn Arbor$177K
- Scott WesthouseGrand Rapids$138K
- Bret HughesDetroit$123K
- Pradeepa YoganathanDetroit$115K
- Jason MillerAnn Arbor$104K
- David TukelDearborn$91K
- Yannis PaulusAnn Arbor$85K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.